Okimoto, Tamio Division of Medical Oncology & Respiratory Medicine, Department of Internal Medicine, Shimane University, Japan
A 40-year-old Japanese man with advanced pulmonary adenocarcinoma harboring anaplastic lymphoma kinase (ALK)-rearranged was administered the selective ALK inhibitor ceritinib as a third-line treatment and continued treatment for nine months. After fourth-line treatment, we performed rechallenge with ceritinib as a fifth-line treatment. On day 54 after rechallenge, the patient developed acutely deteriorating dyspnea. Chest computed tomography showed extensive ground-glass opacities. We diagnosed him with ceritinib-induced interstitial lung disease (ILD) and initiated methylprednisolone pulse therapy. To our knowledge, this is the first report of ceritinib-induced ILD in a Japanese patient. Since it may newly emerge with rechallenge therapy, close attention is necessary.
interstitial lung disease
anaplastic lymphoma kinase
イッパン シャダンホウジン ニホン ナイカ ガッカイ
The Japanese Society of Internal Medicine
Faculty of Medicine